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ABSTRACT
The precise regulation of S-phase–specific genes is
critical for cell proliferation. How the repressive
chromatin configuration mediated by the retino-
blastoma protein and repressor E2F factors
changes at the G1/S transition to allow transcription
activation is unclear. Here we show ChIP-on-chip
studies that reveal that the chromatin remodeller
CHD8 binds 2000 transcriptionally active
promoters. The spectrum of CHD8 target genes
was enriched in E2F-dependent genes. We found
that CHD8 binds E2F-dependent promoters at the
G1/S transition but not in quiescent cells.
Consistently, CHD8 was required for G1/S-specific
expression of these genes and for cell cycle re-entry
on serum stimulation of quiescent cells. We also
show that CHD8 interacts with E2F1 and, import-
antly, loading of E2F1 and E2F3, but not E2F4,
onto S-specific promoters, requires CHD8.
However, CHD8 recruiting is independent of these
factors. Recruiting of MLL histone methyl-
transferase complexes to S-specific promoters
was also severely impaired in the absence of
CHD8. Furthermore, depletion of CHD8 abolished
E2F1 overexpression-dependent S-phase stimula-
tion of serum-starved cells, highlighting the essen-
tial role of CHD8 in E2F-dependent transcription
activation.
INTRODUCTION
The decision about when DNA should be replicated is
probably one of the most controlled processes in the
cell. Therefore, repression of genes required for prolifer-
ation during G0 and early G1 phases of the cell cycle, and
activation of genes speciﬁc for S phase, are tightly
controlled processes that are critical during normal differ-
entiation and tissue homeostasis and that seem to be
disregulated in most cancers (1,2). E2Fs comprise a large
family of transcription factors that bind promoter regions
and are of paramount importance in regulating cell pro-
liferation (3,4). Based on functional studies and amino
acid sequence analyses, classical E2F family members
can be divided into the two canonical classes: repressor
E2Fs (E2F4 and E2F5) or activator E2Fs (E2F1–E2F3),
although exceptions to this canonical classiﬁcation has
been reported (5). During interphase or under quiescent
conditions, E2F4 and E2F5 associate with the retinoblast-
oma (RB) family of pocket proteins (RB, p107 and p130)
and repressor complexes to inhibit transcription of G1/S
transition genes [reviewed in (6)]. On growth factor stimu-
lation, speciﬁc cyclin-dependent kinases phosphorylate
pocket proteins and disrupt their inhibitory activity.
This leads to the induction of activator E2Fs, which
then substitute their repressor counterparts and promote
the expression of genes required for S phase, through a
unclear mechanism that involve histone modiﬁcations
and chromatin remodelling [reviewed in (7)].
CHD8 is a human ATP-dependent chromatin remodel-
ling protein of the SNF2 family, homologue of the
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Trithorax group (TrxG) protein Kismet from Drosophila
(8,9). Ectopic expression studies have shown that CHD8
represses b-catenin target genes, and suppresses p53-
dependent activation and apoptosis, by promoting
histone H1 recruitment (10–13). However, biochemical
studies have shown that CHD8 copuriﬁes with transcrip-
tion activation complexes, such as the MLL complexes
(11,14–16), and with elongating RNAPII (17).
Accordingly, the activity of CHD8 as a transcription
activator has also been reported. CHD8 cooperates
with the androgen receptor for gene activation (18) and
activates expression of cyclin E2 (CCNE2) and
thymidylate synthetase (TYMS) genes (17,19).
Here we show by ChIP-on-chip (ChIP-chip) analysis
that CHD8 binds to the promoter of 2000 active genes
that are also enriched for H3K4me2 and H3K4me3
marks. In agreement with this result, artiﬁcial recruitment
of CHD8 to a synthetic promoter activated transcription.
We found that E2F binding motives were strongly
enriched in promoters containing CHD8, suggesting that
CHD8 may be involved in E2F-dependent transcription.
Analysis of a subset of E2F and CHD8 targets
demonstrated that CHD8 is crucial for the timely activa-
tion of E2F-dependent promoters. Consistently, CHD8
was essential for normal cell cycle re-entry on serum
stimulation. The presence of CHD8 is required for
E2F1, E2F3 and the MLL histone methyltransferase
complexes to be loaded onto G1/S transition promoters.
Therefore, our data demonstrate that CHD8 is a critical
factor for gene activation during the G1/S transition.
MATERIALS AND METHODS
Cell culture and experimental conditions
C33A (human cervix carcinoma), HEK-293 (human
embryonic kidney) and COS7 (green monkey kidney ﬁbro-
blast) cell lines were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM), and the RPE-1 (immortalized
retina epithelium) cell line was maintained in DMEM F12
Ham. In both cases, medium was supplemented with 7%
fetal bovine serum (FBS), 100U/ml penicillin and 100 mg/
ml streptomycin, and cells were cultivated in a 37C incu-
bator with 5% CO2. For RPE-1 cells synchronization,
cells were grown exponentially (in 10% FBS) and then
subjected to serum starvation during 48 h. After that,
cells were collected (0%) or medium was replaced with
fresh medium supplemented with 20% FBS for the
indicated times. For cell cycle analysis, cells were washed
with cold 1PBS, ﬁxed in 70% ethanol and stained with
an analysis solution of 0.25mg/ml ribonuclease A (Sigma)
and 0.05mg/ml propidium iodide (Sigma) in 1PBS.
Samples were analysed using a FACS Calibur machine
(BD Biosciences), CellQuest analysis software and
ModFit program.
ChIP assays
ChIP assays were performed as described (20) using
anti-CHD8 (A301-224A) and anti-E2F1 (A300-766A)
from Bethyl Laboratories; anti-RNAPII (N-20) (sc-899),
anti-E2F3 (sc-878) and anti-E2F4 (sc-1082) from Santa
Cruz Biotechnology; anti-WDR5 (ab56919), anti-
H3K4me3 (ab8580) and anti-H3K4me2 (ab32356) from
Abcam and an anti-CHD8 antibody home made (17).
Chromatin was sonicated to an average fragment size of
400–500 bp using the Diagenode Bioruptor. Rabbit IgG
(Sigma) was used as a control for non-speciﬁc interactions.
Input was prepared with 10% of the chromatin material
used for immunoprecipation. Input material was diluted
1:10 before PCR ampliﬁcation. Quantiﬁcation of immuno-
precipitated DNA was performed by real-time PCR
(qPCR) with the Applied Biosystems 7500 FAST real-
time PCR system, using Applied Biosystems Power
SYBR green master mix. Sample quantiﬁcations by
qPCR were performed in triplicate. Sequences of all oligo-
nucleotides are provided in Supplementary Table S1. Data
are the average of at least three independent experiments.
ChIP-chip microarray hybridization and analysis
ChIP was performed as described earlier in text using
the following antibodies: anti-CHD8 (A301-224A,
Bethyl Laboratories), anti-H3K4me3 (ab8580, Abcam)
and anti-H3K4me2 (ab32356, Abcam). Then, input
(100 ng) and ChIP DNA were ampliﬁed with the
GenomePlex complete whole genome ampliﬁcation
WGA2 kit (Sigma), according to the manufacturer’s rec-
ommended protocol, and subsequently puriﬁed with
Qiaquick Qiagen columns. Input and ChIP-ampliﬁed
DNA were labelled with Alexa Fluor 5 or Alexa Fluor 3
propargyl–linked ﬂuorophores with the BioPrime total
FFPE genomic labelling system following the manufac-
turer’s instructions (Invitrogen). Labelled samples were
puriﬁed with silica-based PureLink spin columns
(Invitrogen). Labelled ampliﬁed DNAs were then
combined and hybridized to an Agilent’s 1Mb Custom
Human Promoter-CpG island microarray, designed with
Agilent’s eArray application (https://earray.chem.agilent.
com/earray). The custom microarray was made out of
two different microarrays for epigenetic studies designed
by Agilent: (i) human promoter ChIP-on-chip set
(2 244 k), which contained extended promoter regions
ranging from 5.5 kb upstream and 2.5 kb downstream of
the TSS, of 17 000 promoters; and (ii) human DNA
methylation microarray (1 244 k), which contained
27 627 expanded CpG islands and 5081 unmethylated
regions. Hybridization and washes were performed as
described by Agilent in a SureHyb hybridization
chamber (Agilent). Arrays were then immediately
scanned on a G2565C DNA microarray scanner
(Agilent). Images were quantiﬁed using Agilent Feature
Extraction Software (version 10.7). Raw ratios between
immunoprecipitated and input DNAs in log2 scale
were analysed with the R software (www.r-project.org)
using the Ringo package adapted for Agilent arrays (21)
available through Bioconductor. Data were normalized
and smoothed, and peaks were detected using the
upperBoundNull non-parametric approach. A signiﬁ-
cantly enriched peak was deﬁned by the following
criteria: the minimum number of enriched probes within
a peak was set to three, the maximum amount of base
pairs at which enriched probes were condensed into one
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enriched peak was set to 600 and the P was required to be
<0.01. Data have been deposited in GEO with accession
number GSE51564.
Microarray expression analysis
Total RNA was isolated in triplicate from exponentially
growing C33A cells using RNeasy Mini Kit (Qiagen).
Purity and quality of isolated RNA were assessed by RNA
6000 Nano assay on a 2100 Bioanalyzer (Agilent
Technologies, Santa 6 Clara, CA, USA). RNA (100ng)
was used for production of end-labelled biotinylated
ssDNA. Labelled ssDNA was hybridized to the
GeneChip human Gene 1.0 ST array oligonucleotide
microarray (Affymetrix, Santa Clara, CA, USA) according
to manufacturer’s recommendations. The arrays were
scanned using the GeneChip Scanner 3000 7G
(Affymetrix), and raw data were extracted from the
scanned images and analysed with the Affymetrix
GeneChip Command Console Software (Affymetrix). The
raw array data were preprocessed and normalized using the
Robust Multichip Average method (22). Data were further
processed using oneChannelGUI (23). The log2 intensities
for each probe were used for further analysis. Data have
been deposited in GEO with accession number GSE48926.
Luciferase reporter assays
HEK-293 cells were transfected by calcium phosphate
with the indicated plasmids following the protocol
described in (24). Vectors encoding the luciferase
reporter gene under the control of adenovirus early gene
IV (EIV) minimal promoter, with or without 5Gal4
DNA binding sites (p5Gal4-EIV-LUC and pEIVluc),
were a gift from C. Muchardt. pSG5-Gal4-HP1a,
encoding the HP1a protein fused to the Gal4 DNA-
binding domain, was a gift from R. Losson. pSG5-Gal4-
CHD8 or pSG5-Gal4-CHD8-K842A was generated by
standard PCR and cloning techniques (cloning strategies
details will be provided on request). All transfections were
normalized by measuring the b-galactosidase activity of
the samples, using cotransfection with pAdRSV-bgal
vector, a gift from P. Charnay (25).
RNAi experiments and transfections
All siRNAs were transfected using Oligofectamine
(Invitrogen) according to the manufacturer’s instructions.
The following siRNAs were used: siCHD8#1, 50-GAGCA
AGCUCAACACCAUC-30; siCHD8#2, 50-GUGCUUCU
GGAAUGUUAAC-30; siCHD8#3 50-GAACUACUCCU
AUCUGCAU-30; for siE2F1, 50-AAGUCACGCUAUG
AGACCUCA-30; for siE2F3, 50-CGUCCAAUGGAUG
GGCUGC-30; and siCt, 50-CGUACGCGGAAUACUU
CGA-30. After transfection, cells were grown in exponen-
tial conditions or, as indicated, the medium was replaced
by fresh medium without serum. After 48 h in serum-free
conditions, cells were collected (0%) or medium was
replaced with fresh medium supplemented with 20%
FBS for the indicated times. The downregulation of
CHD8 (Figures 2B, 3C and 4B), E2F1 and E2F3
(Figure 3E) expression was determined by western
blotting. Anti-a-tubulin antibody (Clone DM1A) from
Sigma Aldrich was used as a loading control. When
indicated, 24 h after siRNA transfection, cells were trans-
fected with plasmids expressing E2F1 (pCMV-E2F1,
provided by C. Muchardt), E1A (pCMV-12 S, provided
by F. Thierry) or empty vectors as a control, using
Lipofectamine (Invitrogen) according to the manufac-
turer’s instructions. After 24 h in serum-free conditions,
cells were collected for cell cycle analysis or expression
analysis by RT-qPCR.
RNA extraction and RT-qPCR
Total RNA was prepared by using the RNeasy Kit
(Qiagen), as described in the manufacturer’s instructions;
the step of DNase I digestion was included to avoid po-
tential DNA contamination. cDNA was generated from
800 ng of total RNA using Superscript First Strand
Synthesis System (Invitrogen). cDNA (2 ml) was used as
a template for RT-qPCR. Gene products were quantiﬁed
by qPCR with the Applied Biosystems 7500 FAST real-
time PCR system, using Applied Biosystems Power SYBR
green master mix. Sequences of all oligonucleotides are
provided in Supplementary Table S1. Values were
normalized to the expression of the ACTB housekeeping
gene. Each experiment was performed at least in duplicate,
and qPCR quantiﬁcations were performed in triplicate.
Immunoﬂuorescence
A cilium assembly/disassembly assay was performed as
previously described (26). Speciﬁcally, cells were starved
in serum-free medium for 48 h to induce cilium formation.
Serum was then added back to the medium to stimulate
cilium resorption and cell cycle re-entry. Cells were
harvested at various time points (0 h, 2 h and 24 h) and
ﬁxed with 100% methanol for 7min, permeabilized for
5min in 0.5% Triton X-100/PBS, washed and then
blocked in 3% BSA/PBS. Monoclonal acetylated
a-tubulin mouse antibody (clone 611B) and monoclonal
g-tubulin mouse antibody (clone GTU-88) were purchased
from Sigma Aldrich. Secondary antibodies used were
FITC-conjugated goat anti-rabbit IgG and Texas Red
goat anti-mouse IgG (Jackson ImmunoResearch). Cells
were examined under a motorized upright wide-ﬁeld
microscope (DM6000B; Leica). Image analysis was
carried out using Leica and Adobe Photoshop software.
Coimmunoprecipitation assays
Whole-cell extracts from cells were obtained by lysing the
cells in immunoprecipitation (IP) buffer [50 mM Tris–HCl
(pH 8), 150mM NaCl, 1mM EDTA (pH 8), 1% Triton
X-100, 1mM PMSF and protease inhibitors cocktail
from GE Healthcare]. The extracts were pre-cleared for
3 h at 4C with protein A or protein G–sepharose beads
(GE Healthcare) pre-equilibrated in the same buffer.
The pre-cleared extracts were then incubated overnight
at 4C with 2 mg of the appropriate antibody. Rabbit or
mouse puriﬁed IgG (Sigma) were used as a control.
Immunocomplexes were puriﬁed by adding 30 ml of 50%
protein A or protein G sepharose beads. Finally, after
three washes with IP buffer, bound proteins were eluted
by boiling the beads in Laemmli sample buffer containing
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5% b-mercaptoethanol, separated by SDS/PAGE and
visualized by western blot with the indicated antibodies
using ECL Plus (GE Healthcare), according to the manu-
facturer’s instructions.
RESULTS
CHD8 binds a subset of transcriptionally active genes.
To investigate the target genes of CHD8, ChIP-chip
analysis of C33A human cervical carcinoma cells was per-
formed using a custom-designed promoters and CpG
island Agilent microarray. Two independent ChIP-chip ex-
periments produced similar enrichment ratios (Pearson co-
efﬁcient, r=0.664) (Supplementary Figure S1A). CHD8
was associated (P< 0.01) with the promoter of 2887 and
2476 genes in each experiment, respectively. The 1965
promoter regions that were enriched for CHD8 in both
experiments, were thus considered to be CHD8 target
genes (Supplementary Table S2). CHD8 occupancy was
conﬁrmed by ChIP-qPCR in six selected target genes
(BRD2, RPS18, HMG20A, CAPZA1, COPZ1 and
N4BP1), in contrast, CHD8 was not found in three non-
target genes (ABCA10, DEFB133, MSA4A13), validating
the ChIP-chip results (Supplementary Figure S1B). We
also conﬁrmed that CHD8 was absent from the 30 part of
the CCNE2 gene (Supplementary Figure S1C). We have
previously shown that CHD8 binds H3K4me2 and, to a
lesser extent, H3K4me3, through its tandem chromo-
domains (17). To investigate whether CHD8 binds specif-
ically to the promoters containing these marks, we also
determined the distribution of H3K4me2 and H3K4me3
by ChIP-chip in C33A cells (Supplementary Table S3).
About 95% (1869 promoters) of the CHD8 target pro-
moters also contained H3K4me2 and H3K4me3 marks
(Figure 1A). The CHD8-enriched probe distribution
relative to the transcription start site (TSS) strongly
overlapped with that of the H3K4me2 and H3K4me3
signals (Figure 1B). Thus, as methylated H3K4, CHD8
was enriched not only at the promoters but also at the 50-
end of gene bodies. Furthermore, a strong correlation
between CHD8 enrichment intensities and those of
H3K4me3 (Pearson r=0.643) and H3K4me2 (Pearson
r=0.659) was found (Supplementary Figure S1A). As
H3K4me3 and H3K4me2 modiﬁcations are normally
associated with active promoters these data suggested
that CHD8 is enriched in transcriptionally active genes.
In agreement with this, most of the CHD8 target genes
presented a medium or high transcriptional activity,
based on C33A cells transcripts levels determined from
Affymetrix microarrays (Figure 1C).
To investigate the functional effect of CHD8 binding to
a promoter, we have evaluated the consequences of artiﬁ-
cially recruiting a Gal4-CHD8 fusion protein to a minimal
EIV adenovirus promoter with ﬁve Gal4 DNA-binding
sites that control the expression of a luciferase reporter
gene. As control, we also determined the effect of recruit-
ing the typical repressor factor heterochromatin protein 1
alpha (HP1a) (27). As shown in Figure 1D, Gal4-HP1a
expression led to a 10-fold decreased reporter gene expres-
sion. In contrast, expression of Gal4-CHD8 increased
7-fold luciferase activity indicating that CHD8 is able
to activate transcription when artiﬁcially recruited to a
promoter. Interestingly, a point mutation in the ATP
binding site of CHD8 (CHD8-K842A), which abolished
the in vitro chromatin remodelling activity of the protein
(11), partially impaired Gal4-CHD8-dependent transcrip-
tion activation. Expression of the reporter system lacking
Gal4 binding sites was largely independent of the presence
of Gal4 fusion proteins (Figure 1D). Therefore, our data
indicate that CHD8 is able to activate transcription when
recruited to a promoter, and that this function is, at least
in part, dependent on its chromatin remodelling activity.
Gene Ontology (GO) analyses using DAVID (28)
software indicated that a large proportion of the CHD8
target genes identiﬁed by ChIP-chip are involved in
macromolecular biosynthetic processes (transcription,
mRNA processing and translation), chromatin organiza-
tion (histones and chromatin-associated factors) and cell
cycle (Supplementary Figure S1D). Consistently, we
found that CHD8 targets were strongly enriched in E2F
binding sites (P=1.31 1064) (Supplementary Figure
S1E). Thus, 67% of the CHD8-bound promoters also
contain E2F binding sites (1314 promoters).
Furthermore, using ENCODE ChIP-seq data, we found
that 32% of CHD8 target promoters were occupied by
E2F1 in HeLa cells (P=3.3 1057), another cervical
carcinoma cell line (Figure 1E). These data suggested
that CHD8 has a role in regulating E2F target genes.
CHD8 controls expression of E2F targets.
We next investigated how CHD8 affects the cell cycle-
dependent expression of a subset of E2F target genes in a
non-tumorigenic cell line. For this, we used the hTERT-
immortalized retinal pigment epithelial cell line, RPE1,
which presents a normal karyotype and can be efﬁciently
synchronized by serum starvation (29). ChIP-qPCR
analysis in asynchronously growing RPE1 cells, using two
different anti-CHD8 antibodies, indicated that CHD8 was
bound to the promoters of E2F-regulated genes, such as
CCNA2, CDC6, CCNE2 and BRCA2 (Figure 2A and
Supplementary Figure S2). We thus synchronized RPE1
cells at the G0/G1 phase by serum starvation and then
induced cell cycle re-entry by serum re-addition. Flow
cytometry analysis demonstrated that 15% of the cells
had reached S phase 14 h after serum addition, so we con-
sidered this time point to be the late-G1/S transition.
Interestingly, CHD8 was almost absent from E2F-
regulated promoters in quiescent cells, whereas its occu-
pancy was increased between 5- and 20-fold by 14 h after
serum restoration (Figure 2A). Levels of CHD8 mRNA
were not altered by serum deprivation or serum re-
addition (Supplementary Figure S3A). However, amount
of CHD8 protein increased about 3-fold 14 h after serum
restoration (Supplementary Figure S3B). These data
suggest that both promoter binding and stability of
CHD8 are proliferation-regulated processes. Next, we
investigated the effect of CHD8 depletion by short inter-
fering RNAs (siRNA) on the expression of E2F targets.
As expected, CCNA2, CDC6, CCNE2 and BRCA2 genes
were expressed in asynchronous cultures and at the G1/S
transition (14 h timepoint), but their expression in quiescent
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cells was low. Importantly, CHD8 knockdown (Figure 2B)
strongly impaired expression of these genes at the G1/S
transition (Figure 2C). Similar results were obtained with
three siRNA molecules that target different regions of the
CHD8 mRNA (Supplementary Figure S4A). Taken
together, these data indicate that CHD8 is an essential
factor in controlling gene expression at the G1/S transition.
CHD8 is necessary for cell cycle re-entry.
We next decided to investigate the effect of CHD8 deple-
tion on the kinetics of cell cycle progression after serum
stimulation of G0-arrested RPE1 cells. CHD8 depletion
provoked a strong delay of cell cycle progression:
although 88.8% of the control cells were in S or G2/M
phases 20 h after serum addition, only 17.7% of the
CHD8-depleted cells had started DNA replication
(Figure 2D and Supplementary Table S4). Serum-starved
RPE1 cells generate a microtubule-based organelle called
the primary cilium (26,29). These hair-like organelles are
displayed on G0 phase and are resorbed as the cells re-
enter the cell cycle. Thus, as a second way to evaluate the
role of CHD8 in cell cycle re-entry, we assayed the kinetic of
cilia resorption. Serum restoration triggers a biphasic
kinetics of ciliary disassembly, which peaks at 2 h and 24 h
after serum treatment. The ﬁrst wave of cilia shortening
occurs at early G1-phase preceding S phase entry,
whereas the second wave occurs as cells are preparing to
enter the G2/M phase (26). CHD8-depleted cells showed a
normal ﬁrst wave of cilium disassembly 2 h after serum re-
addition (Supplementary Figure S5). However, 24 h after
serum re-addition, 38.4% (±5%) of the CHD8-depleted
cells still presented a visible cilium, compared with 12.1%
(±6%) in the control cells (Supplementary Figure S5). This
indicates that the second wave of cilia disassembly, which is
dependent on cell cycle progression, requires CHD8.
CHD8 is required for promoter loading of E2F1 and
E2F3
The results presented earlier in text indicate that CHD8 is
essential for cell cycle progression and expression of E2F-
dependent genes. Therefore, we decided to investigate in
detail the relationship between CHD8 and these factors.
Mass spectrometry data have shown that CHD8 copurify
with HCFC1 (15,16,30), a well-known E2F-interacting
factor (31). Consistently, both transiently expressed and
endogenous E2F1 proteins were coimmunoprecipitated
with antibodies against CHD8 (Figure 3A and B),
indicating that E2F1 and CHD8 form part of the same
complex. Interestingly, depletion of CHD8 in exponen-
tially growing cells impaired E2F1 and E2F3 occupancy
at the analysed promoters (Figure 3C), as well as RNAPII
recruitment (Figure 3D). In contrast, occupancy of E2F4
was not affected or slightly increased in CHD8-depleted
cells, consistently with the G1 arrest provoked by the
CHD8 deﬁciency. Similar E2F1 recruitment defects were
obtained by using a second siRNA against CHD8
Figure 1. CHD8 binds a subset of transcriptionally active promoters. (A) Venn-diagram showing overlap between CHD8 targets (green) and
H3K4me2- (red) or H3K4me3- (blue) enriched genes. (B) Distribution of CHD8 (green), H3K4me2 (red) and H3K4me3 (blue) enrichment
regions relative to the TSS of RefSeq genes. (C) All genes were binned into ten quantiles based on their transcribed level, as determined by
Affymetrix microarrays [Gene Expression Omnibus (GEO) Accession GSE48926] (x-axis). The y-axis shows the average CHD8 binding frequency
for all genes in each quantile. (D) Luciferase reporter plasmids harbouring an EIV minimal promoter, and containing or not upstream 5Gal4 DNA
binding sites, were cotransfected with empty pSG5 vector (Gal4-Ø) or pSG5-Gal4-HP1a (Gal4-HP1a) as a negative control or with pSG5-Gal4-
CHD8 (Gal4-CHD8) or pSG5-Gal4-CHD8-K842A (Gal4-CHD8 K842A) (which encode for the given proteins fused to the Gal4 DNA-binding
domain), in 293 cells. Data are expressed as the mean activity from three independent experiments±SD values. (E) Venn-diagram showing overlap
between CHD8 (green) and E2F1 (brown) binding genes. E2F1 data set in HeLa-S3 cells (GSM935484) was obtained from ENCODE database
stored in GEO. A P-value of 3.3 1057 was calculated using the hypergeometric distribution.
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(Supplementary Figure S4B). Depletion of E2F1 or E2F3
(Figure 3E) did not signiﬁcantly affect CHD8 occupancy
at any of the genes tested (Figure 3F), despite the fact that
RNAPII levels were decreased (Figure 3G). These data
suggest that CHD8 has an essential role in mediating
chromatin loading of activating E2Fs onto the G1/S-
speciﬁc genes. E2F1 knockdown experiments have
demonstrated a requirement for this E2F protein in
allowing cells to enter cell cycle from quiescence (32).
Then, we characterized the kinetics of the recruitment
for CHD8 and E2F1 at the G1/S-speciﬁc promoters
during cell cycle re-entry in the absence of each other.
Samples were taken under quiescent conditions or 1 and
14 h after adding serum to quiescent cells. In control cells,
a high level of CHD8 and E2F1 occupancy was reached
14 h after serum addition. Strikingly, a small but signiﬁ-
cant increase, more evident in the case of CHD8, was
already observed after 1 h (Figure 3H), many hours
before the G1/S transition. As a control, we veriﬁed
that silencing CHD8 or E2F1 strongly decreased their
association with chromatin, validating the ChIP signals.
Consistent with the results of asynchronous cultures,
depletion of CHD8 strongly impaired E2F1 recruitment.
In contrast, E2F1 depletion did not signiﬁcantly affect
CHD8 recruitment neither at 1 h nor at 14 h on serum
re-addition, indicating that CHD8 recruitment is also
independent of E2F1 under these circumstances.
Our data indicate that CHD8 is directly or indirectly
required for loading activator E2F factors at G1/S transi-
tion promoters on serum stimulation of quiescent
cells. To demonstrate a direct role of CHD8 in E2F
function, we decided to investigate CHD8 requirement on
E2F-dependent cell cycle activation in a serum-independent
manner. It is well know that overexpression of E2F1 is able
to trigger quiescent cells into S phase (33). Interestingly,
depletion of CHD8 abolished E2F1-dependent S phase
stimulation of serum-starved cells (Figure 4A and B). In
agreement with the previous results, overexpression of
Figure 2. CHD8 binds and controls expression of E2F-dependent genes. (A) ChIP analysis of CHD8 on selected E2F-dependent genes. RPE1 cells
were either grown exponentially (in 10% FBS) or serum-starved for 48 h (0%) and then serum stimulated (FBS 20%) for the indicated times.
(B) Efﬁciency of CHD8 knockdown was analysed by western blotting of proliferating (10% FBS) or serum starved (0% FBS) and then serum
stimulated (1 h and 10 h 20% FBS) RPE1 cells that had been transfected with control siRNA (siCt) or siRNA against CHD8 (siCHD8) using
siCHD8#1. (C) RT-qPCR analysis of expression of selected E2F-dependent genes in RPE1 cells transfected with control siRNA (siCt) or siRNA
against CHD8 (siCHD8). Cells were serum starved and then serum stimulated as in (A). (D) Cell cycle analysis by ﬂow cytometry of control (siCt) or
CHD8-depleted (siCHD8) RPE1 cells, either grown exponentially (10%) or serum-starved and then stimulated with 20% FBS for the indicated times.
A representative experiment is shown. (A and C) Data (% input or mRNA relative level) are the mean of at least n=6 qPCR reactions from three
independent experiments. Error bars represent±SD values.
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Figure 3. CHD8 interacts with E2F1 and it is required for E2F1 and E2F3 normal recruiting to G1/S-speciﬁc promoters. (A and B) Cell extracts
from COS-7 cells transfected with a plasmid expressing E2F1 (A) or from RPE1 cells serum starved and then stimulated with 20% FBS for 14 h (B)
were subjected to immunoprecipitation (IP) and analysed by western blotting with antibodies against CHD8 and E2F1. (C and D) ChIP analysis
of E2F1, E2F3 and E2F4 (C) or RNAPII (D) on the indicated promoters, in exponentially growing RPE1 cells transfected with control (siCt)
or CHD8-speciﬁc (siCHD8) siRNAs. Inset in (C) shows level of CHD8 expression analysed by western blotting. (E) E2F1 and E2F3 expression of
proliferating RPE1 cells after transfection with control (siCt) or either E2F1 (siE2F1)- or E2F3 (siE2F3)-speciﬁc siRNAs, was analysed by west-
ern blotting. (F and G) ChIP analysis of CHD8 (F) and RNAPII (G) on the indicated promoters, in exponentially growing RPE1 cells transfected
with control (siCt) or either E2F1 (siE2F1) or E2F3 (siE2F3)-speciﬁc siRNAs. (H) ChIP analysis of CHD8 and E2F1 in RPE1 cells serum
starved (0 h) and then stimulated with 20% FBS for 1 or 14 h. Cells were transfected with control siRNA (siCt) or siRNA against CHD8
(siCHD8) or E2F1 (siE2F1). (C, D and F–H) Data (% input) are the mean of at least n=6 qPCR reactions from three independent experiments.
Error bars represent±SD values.
Figure 4. CHD8 is required for E2F1-dependent S phase stimulation of quiescent cells. (A-C) RPE1 cells were transfected with control (siCt) or
CHD8-speciﬁc (siCHD8) siRNAs and then serum starved for 24 h. After that, cells were transfected with a plasmid expressing E2F1 (E2F1) or empty
vector (Ø), maintained in serum starvation conditions for 24 h, and ﬁnally collected for cell cycle analysis by ﬂow cytometry (A), for western blotting
analysis (B) or for expression analysis by RT-qPCR (C). (B) Western blottings were performed with anti-CHD8 and anti-E2F1 antibodies. (C) Total
RNA was subjected to RT-qPCR quantiﬁcation with primers for the indicated genes. Data (mRNA relative level) are the mean of at least n=6
qPCR reactions from three independent experiments. Error bars represent±SD values.
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E2F1 induced expression of the G1/S transition genes
CCNE2 and BRCA2 in control cells but not in CHD8-
depleted cells (Figure 4C), suggesting that CHD8 directly
facilitates E2F1 function. Similarly, CHD8 was also
required for induction of CCNE2 and BRCA2 genes on
overexpression of the adenovirus E1A oncoprotein
(Supplementary Figure S6), which it is known to
overcome repression of G1/S-speciﬁc genes by disrupting
the interaction of RB protein with E2Fs and other
corepressors (34).
CHD8 is required for recruitment of MLL complexes to
G1/S-speciﬁc promoters
It has been reported that CHD8 copuriﬁes with mem-
bers of the MLL complexes of H3K4 methyltransferases
(11,14–16). In addition, it was shown that CHD8 directly
interacts with WDR5, a common component of MLL1,
MLL2 and hSet1-associated complexes (14). Therefore,
we also studied whether CHD8 depletion affects the
recruitment of WDR5 and the methylation marks
introduced by the MLL complexes. WDR5 promoter
occupancy and levels of H3K4 di- and tri-methylation
were determined under quiescent conditions or 1 and
14 h after serum re-addition. Control cells showed a sig-
niﬁcant augment of WDR5 occupancy and H3K4 methy-
lation 1 h after serum addition that further increased at
14 h, indicating that MLL complexes recruitment begins
many hours before the G1/S transition. We observed that
depletion of E2F1 almost completely abolished recruit-
ment of WDR5 and H3K4 di- and tri-methylation at
the CCNA2, CDC6, CCNE2 and BRCA2 promoters
(Figure 5A and B), indicating that other activator E2Fs
play a minor role in MLL complexes recruitment to these
genes, in RPE1 cells. In agreement with the fact that
CHD8 is required for E2F1 loading, depletion of CHD8
also strongly reduced occupancy of WDR5 and H3K4
methylation in the four promoters analysed (Figure 5A
and B). These results place CHD8 recruitment as an
event required for E2F1 loading and the subsequent
recruitment of MLL complexes.
DISCUSSION
Here, we demonstrate that the chromatin remodeller
CHD8 binds the promoters of a subset of transcriptionally
active genes enriched in H3K4me2 and H3K4me3 marks,
many of which are related to macromolecular biosynthesis
and cell proliferation. Additionally, we show that CHD8
leaves G1/S gene promoters under quiescent conditions.
CHD8 recruiting occurs shortly after serum stimulation
of quiescent cells, far earlier than transcription is
activated, suggesting that the chromatin of G1/S transi-
tion genes is starting to change several hours before the
G1/S transition. Finally, we demonstrate that CHD8 is
required for the recruitment of E2F1, E2F3, MLL
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Figure 5. CHD8 is required for MLL complexes recruitment and histone H3K4 methylation of G1/S promoters. (A and B) ChIP analysis of WDR5
(A), H3K4me2 and H3K4me3 (B) on the indicated promoters, in RPE1 cells serum starved (0 h) and then stimulated with 20% FBS for 1 or 14 h.
Cells were transfected with control siRNA (siCt) or siRNA against either CHD8 (siCHD8) or E2F1 (siE2F1). Data (% input) are the mean of at
least n=6 qPCR reactions from three independent experiments. Error bars represent±SD values.
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complexes and RNAPII to G1/S transition promoters,
and therefore for E2F-dependent transcription activation
and cell cycle progression.
Our data now demonstrate that CHD8 plays a positive
role in transcription, in addition to its previously reported
in repressing p53- and b-catenin-dependent gene expres-
sion (10–13). Speciﬁcally, our ChIP-chip experiments
showed that CHD8 mostly binds to promoters of tran-
scriptionally active genes that also contain high levels of
H3K4me2 and H3K4me3, two post-transcriptional modi-
ﬁcations typical for active promoters. In addition, CHD8
was absent or poorly enriched in repressed genes. We also
demonstrated that artiﬁcial recruitment of CHD8 to a
minimal promoter provoked transcription activation.
Furthermore, expression of G1/S transition genes was
impaired in CHD8-depleted cells. Similarly to CHD8,
the Drosophila orthologous Kismet is found in transcrip-
tionally active genes in polytene chromosomes (35).
Obviously, our data do not preclude that CHD8 also
plays a role in repression. Roles as activators and repres-
sors have been described for other remodellers of the
SNF2 family and their associated complexes (36,37).
The CHD subfamily of SNF2 proteins is characterized
by the presence of two tandem chromodomains that are
amino terminal to the SNF2 ATPase/helicase domain.
There are three distinct groups within the human CHD
subfamily: CHD1/2, CHD3/4/5, and CHD6/7/8/9 (8).
CHD6/7/8/9 are paralogous genes related to the
Drosophila Kismet gene. Genome-wide studies have
shown that CHD7 is mostly associated to a subset of
active enhancers and promoters in mice ES cells (38).
Furthermore, it has been recently shown that CHD7 inter-
acts with CHD8 (39). Using ENCODE ChIP-seq data of
the distribution of CHD7 in K562 cells, we have found that
5.7% (112) of the CHD8-bound promoters in C33A cells
are bound by CHD7. Among the overlapping genes, those
for ribosomal proteins (P=5.7 109) and chromatin
architectural proteins (P=4.4 1013) are highly repre-
sented. The low number of overlapping genes may be the
consequence of the different cell lines used for the study.
Nevertheless, gene ontology analysis of the CHD7-bound
genes did not indicate any association with cell cycle genes,
suggesting that although CHD8 and CHD7 may share a
number of targets, they also have gene-speciﬁc targets.
We have previously shown that CHD8 depletion in asyn-
chronous cultures provokes a growth defect and a small G1
arrest in the C33A tumour cell line (17). In this cell line,
CHD8 was constitutively bound to the promoter of
CCNE2 gene throughout the cell cycle, as well as in
serum-deprived cells [(17) and our unpublished results].
However, we failed to achieve growth arrest by serum
deprivation in C33A cells, and therefore decided to use
the non-transformed cell line of RPE1. With these cells,
we showed that CHD8 occupancy at G1/S target gene
promoters dramatically decreased in quiescent cells, and
that its binding to G1/S promoters, including CCNE2,
was dependent on serum re-addition. Furthermore, we
showed that CHD8 was absolutely required for cell cycle
progression following serum re-addition. As growth
factors-independent proliferation is a hallmark of many
types of tumours (40), it will be interesting to investigate
whether the presence of CHD8 in the absence of serum at
G1/S promoters is a general characteristic of cancer cells.
We show that CHD8 binds to more than a thousand
promoters containing E2F binding sites, including
many G1/S transition-speciﬁc genes. E2F-dependent tran-
scription activation is a ﬁnely controlled process that
requires extensive chromatin changes from a repressed
RB-mediated state, characterized by the presence of
repressive histone marks such as H3K9m2/3, H3K27me2/
3, H4K20me and low acetylation, to an active state
characterized by acetylated histones and methylated
H3K4 (7). This is an interesting example of how
Polycomb complexes and Polycomb-mediated histone
marks are substituted by TrxG complexes and marks in a
not yet fully understood way (41,42). We demonstrate that
depletion of CHD8 (a human TrxG protein) severely
impaired E2F1 and E2F3 loading onto 4 different E2F-
dependent promoters, suggesting that CHD8 is required
for the substitution of the repressor E2F factors by the
activator E2Fs. Furthermore, depletion of CHD8 also
impairs WDR5 occupancy and H3K4 methylation at
these promoters. The WDR5/Ash2L/RbBP5 subcomplex
forms part of several MLL complexes but can also form
a subcomplex independently of MLL proteins (43,44).
It has been shown that CHD8 directly interacts with
the three components of the WDR5/Ash2L/RbBP5 sub-
complex (14). However, our data demonstrate that in the
absence of E2F1, CHD8 binds but WDR5 does not bind to
G1/S promoters, suggesting that CHD8 is loaded onto the
chromatin independently of the WDR5/Ash2L/RbBP5
subcomplex and before H3K4 methylation occurs. How
does CHD8 activate transcription is by the moment
unclear. CHD8, through its ATP-dependent chromatin
remodelling activity, may contribute to promote an open
chromatin conﬁguration that allows activator E2Fs
binding. We have shown that the ATPase activity of
CHD8 is partially required for transcription activation of
a chimeric promoter, indicating that part of its transacti-
vation activity is independent of the remodelling activity.
It has been previously shown that CHD8 interacts with
RNAPII (17) and with subunits of the MLL complexes
(11,14–16), and in this work we show that CHD8 also inter-
acts with E2F1. Taken together, these data suggest that
CHD8 also acts as a scaffolding protein that establishes
contacts with several components essential for the activa-
tion of G1/S promoters, and that its absence avoids subse-
quent steps of gene activation. Therefore, our results
suggest an order to the events occurring at E2F target pro-
moters on activation of quiescent cells, where CHD8
binding and activity precedes activators E2F binding,
that then lead to MLL complexes binding, H3K4 methy-
lation and RNAPII recruitment (Figure 6). However, one
issue remains obscure: how is CHD8 recruited to chroma-
tin? Analysis of the more common transcription factor
binding sites in the CHD8-bound promoters showed that,
in addition to E2F sites, ELK1 binding sites were also
strongly represented (9.19 1039). ELK1 is directly
activated through its phosphorylation by MAPK on
growth factors stimulation (45). ELK1 can function in
transcriptional activation by cooperatingwith the serum re-
sponse factor (SRF) through protein–protein interactions
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and also through the close positioning of their DNA
binding sites (46,47). Interestingly, an interaction of
CHD8 with serum response factor has been previously
reported (48). Another possibility is that CHD8 is recruited
by its interaction with a chromatin mark. We have previ-
ously shown that the chromodomains of CHD8 interact
with H3K4methylated peptides in vitro, with a strong pref-
erence for H3K4me2 (17). Consistently with these results,
now we observe that the proﬁle of CHD8 occupancy
around TSS exactly matches that of H3K4me2 (Figure
1B), suggesting that CHD8 also displays higher afﬁnity
for this modiﬁcation in vivo. We also show that H3K4
methylation was dependent on CHD8 in G1/S promoters,
and therefore it seems unlikely that H3K4 methylation is
essential for CHD8 recruitment. However, we cannot
exclude that CHD8 activity triggers a positive feed-
forward loop for activator complexes assembly where
binding of activator E2F and MLL complexes increases
H3K4 methylation and promotes stabilization and add-
itional recruitment of CHD8 at the promoters.
Another ATP-dependent chromatin remodelling
machine also play a role in E2F-dependent activation: a
subset of SWI/SNF complexes (also called BAF
complexes) containing the ARID1B subunit are associated
with E2F-dependent genes at late G1 and S phases and
depletion of ARID1B impairs expression of E2F targets
(49). What is the interplay between SWI/SNF and CHD8
and what are the speciﬁc events of nucleosome re-
modelling performed by each machinery are unsolved
questions. However, it is worth noting that CHD7, a
CHD8 paralogue, interacts with SWI/SNF complexes
(50). Furthermore, peptides from CHD8 were discovered
in a proteomic analysis of SWI/SNF complexes, so the
two machineries may functionally interact (51).
All together, our data reveal an essential role for CHD8
in cell cycle re-entry and progression. Alterations in the
regulation of the RB-E2F pathway are common events in
cancer (3). Thus, inactivation of the tumour suppressor
gene RB or deregulated expression of E2F proteins has
been detected in many human cancers. Here we show
that depletion of CHD8 was able to suppress E2F1
overexpression-mediated induction of cell cycle in quies-
cent cells. Furthermore, analyses of publicly available
gene expression sets using the ONCOMINE or
NEXBIO databases revealed that CHD8 is signiﬁcantly
upregulated in esophageal adenocarcinoma (P=6.32
105) (52), ovarian carcinoma (P=1.98 109) (53),
lung adenocarcinoma (P=2.9 109) (54) and prostate
cancer (P=0.0009) (55), suggesting a positive role of
CHD8 in tumour formation. We believe that these
results support investigating a possible role for CHD8
inhibitors as anti-cancer drugs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online,
including [56,57].
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